Modality
mAb
MOA
EZH2i
Target
Tau
Pathway
Cell Cycle
AngelmanParkinson'sWM
Development Pipeline
Preclinical
~May 2023
→ ~Aug 2024
Phase 1
Nov 2024
Phase 1Current
NCT04650784
2,581 pts·Angelman
2024-11→TBD·Completed
2,581 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1/2
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04650784 | Phase 1/2 | Angelman | Completed | 2581 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Tezetapinarof | CG Oncology | Phase 3 | VEGF |